The Imaging Response Criteria were developed originally for objectively assessing treatment response of solid tumorin oncologic clinical trials.
Generally speaking imaging response criteria encompass a set of rules that define/guide the assessment of change in tumor burden along a treatment course based on repeated imaging exams. At this moment imaging assessment of treatment response is more relevant to the clinical trials imaging of drug development than to clinical service imaging practiced routinely at hospitals. However oncology patients are receiving more and more complex therapies which results in growing needs to apply imaging response criteria and advanced quantitative imaging techniques to evaluate tumor response to treatment in hospital settings.
Conventional response criteria, RECIST and WHO, assess the tumor size by means of uni- and bi-dimensional measurements on 2D cross section images. Today tumor size is still the most accepted imaging biomarker.
As more and more targeted therapeutic agents become available in clinical practice and treatment response observed with targeted therapeutics can be different from that observed with conventional chemotherapies we see the new response criteria been developed and is proliferating to daily clinical practice. Therefore it is necessary not only to introduce the new response criteria coping with novel cancer therapies but also bring in deployment assistance into clinical routine in hospital settings.
Contact us for more information about our imaging product and service: [email protected]